NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel and Business Development, will transition from her role and cease serving as General Counsel effective September 21, 2026. Ms. Olivo will remain an employee until October 2, 2026 for transitional purposes and is eligible for separation payments consistent with her employment agreement. This executive departure represents a material change in key leadership. NeoGenomics operates in the healthcare industry, providing molecular diagnostic testing services.

NeoGenomics, Inc. reported second-quarter 2026 results with total revenue increasing 11% year-over-year to $202 million, driven by a 14% rise in clinical revenue and 26% growth in next-generation sequencing. The company recorded GAAP net income of $2 million, including an $11 million gain on debt extinguishment, and delivered adjusted EBITDA of $14 million, up 36%. NeoGenomics raised its full-year 2026 revenue guidance to a range of $802–$806 million and adjusted EBITDA guidance to $56–$58 million. The quarter also saw the completion of a $316 million private offering of 0.75% convertible senior notes due 2032, used to repurchase approximately $276 million of existing convertible notes and $25 million in common stock. NeoGenomics operates in the healthcare diagnostics industry, providing oncology testing and precision medicine solutions.

NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice on July 20, 2026, to resolve an investigation into consulting and service agreements regarding federal healthcare laws. The company agreed to pay $9,813,260 to resolve the matter, which was previously addressed via a $11.2 million reserve accrued as of March 31, 2026. The settlement does not constitute an admission of liability. NeoGenomics, Inc. is a healthcare company providing precision oncology diagnostics.

NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice to resolve an investigation into consulting services provided to healthcare providers. The company agreed to pay $9,813,260 plus 4.250% annual interest from January 16, 2026, to resolve the matter, utilizing a previously accrued reserve of $11.2 million. NeoGenomics is a cancer diagnostics company specializing in cancer genetics testing and information services.

NeoGenomics, Inc. completed an offering of $316.25 million in 0.75% Convertible Senior Notes due 2032, which included an additional $41.25 million in notes. The company also entered into capped call transactions to reduce potential dilution, costing approximately $28.7 million. Concurrently, the company repurchased approximately $276.0 million of its existing 0.25% convertible senior notes due 2028 for a total cost of $263.19 million. NeoGenomics, Inc. is a healthcare company providing oncology-focused diagnostic services.